Cord Blood News Volume 3.10 | Mar 17 2011

Webinar: ALDH^br Cells and Regenerative Medicine
Aldehyde Dehydrogenase bright (ALDH^br) cells have been used in preclinical models and human clinical trials in applications such as critical limb ischemia, ischemic stroke, acute liver failure and ischemic heart failure.¹ Learn more about how ALDH^br cells could be used in regenerative medicine by registering today for an exclusive webinar presented by Dr. Andrew E. Balber of Cicada Biopharmaceutical Consulting.

Join us on April 7 at:
10AM EST (ideal for Europe) | 2PM EST (ideal for Americas) | 8PM EST (ideal for Asia-Pacific)

1Reviewed in Balber AE. Stem Cells (in press). DOI: 10.1002/stem.613.
Dr. Balber holds equity in and is a consultant to Aldagen, Inc., a company that is developing research, diagnostic, and therapeutic products based on detecting and isolating ALDH^br cells.

 “Like” Cell Therapy News on Facebook for a chance to win an Amazon gift card!

 Follow us on Twitter! @Cord_Blood_News

Interested in recruiting talented individuals? Post your career opportunities in Cord Blood News at no cost. Contact us at info@connexoncreative.com

Hepatic Differentiation of Amniotic Epithelial Cells
Amniotic epithelial cells possess the ability to differentiate into cells with characteristics of functional hepatocytes, in vitro and in vivo, thus representing a useful and non controversial source of cells for transplantation. [Hepatology]

Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of CD20 Expression in Acute Lymphoblastic Leukemia
Results can serve as a reference to evaluate incorporation of anti-CD20 therapeutics to hematopoietic stem cell transplantation for the CD20+ acute lymphoblastic leukemia subset. [Blood]

Autologous Stem Cell Transplantation as a First-Line Treatment Strategy for Chronic Lymphocytic Leukemia: A Multicenter Randomized Controlled Trial
Researchers conducted a prospective randomized trial of autologous stem cell transplantation in previously untreated chronic lymphocytic leukemia patients. [Blood]

Cardiac Tamponade Potentially Related to Sirolimus Following Cord Blood Transplantation
Researchers present the case of a 28-year-old female patient with advanced myelodysplastic syndrome. [Bone Marrow Transplant]

Initial CD34+ Cell-Enrichment of Cord Blood Determines Hematopoietic Stem/Progenitor Cell Yield Upon Ex Vivo Expansion
Findings stress the importance of establishing a balance between the cell proliferative potential and cell recovery upon purification, towards the efficient and cost-effective expansion of hematopoietic stem/progenitor cells for cellular therapy. [J Cell Biochem]

Ex Vivo Rapamycin Treatment of Human Cord Blood CD34+ Cells Enhances Their Engraftment of NSG Mice
Since overexpression of Rheb2 leads to increased signaling through mTOR, researchers examined the effect of the mTOR inhibitor rapamycin ex vivo on cytokine expanded CD34+ cord blood cells for the engraftment of these cells in non-obese diabetic, severe combined immunodeficient, IL-2 receptor γ chain null (NSG) mice. [Blood Cells Mol Dis]

Secondary Pulmonary Alveolar Proteinosis After Unrelated Cord Blood Hematopoietic Cell Transplantation
Researchers observed two cases of pulmonary alveolar proteinosis after unrelated cord blood hematopoietic progenitor cell transplantation in children with ALL. [Pediatr Transplant]

The Methods Used to Collect Hematopoietic Stem Cells
The methods used to collect hematopoietic stem cells in their natural environment (bone marrow or cord blood) or in the peripheral blood after stimulation are well-defined and ruled both to ensure the donor security and perform a quality hematopoietic transplantation. [Transfus Clin Biol]

bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia
bluebird bio announced that it has entered into an agreement with the French Muscular Dystrophy Association, a French non-profit entity, whereby the company will receive an initial amount of approximately $1.4 million in cash to support the development of LentiGlobin®, the company’s development-stage program for the treatment of beta-thalassemia and sickle cell anemia. [bluebird bio Press Release]

NEW International Society for Cellular Therapy (ISCT) 17th Annual Meeting
May 18-21, 2011
Rotterdam, The Netherlands

NEW American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-21, 2011
Seattle, United States

NEW International Society for Hematology and Stem Cells (ISEH) 40th Annual Scientific Meeting
August 25-28, 2011
Vancouver, Canada

Visit our events page to see a complete list of events in the cord blood community.

Implementation Coordinator – Maternity Leave Contract (STEMSOFT Software Inc.)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Supervisor Cell Therapy Laboratory – Cord Blood Bank (The University of Texas MD Anderson Cancer Center)

Supervisor Cell Therapy Lab (The University of Texas MD Anderson Cancer Center)

Cell Therapy Manufacturing Manager (Opexa Therapeutics)

Postdoctoral Fellow (The Henry M. Jackson Foundation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.